Healthcare Resource Use and Cost: The Impact of Adopting an Abuse-Deterrent Formulation of Extended Release Morphine

BACKGROUND: Development of abuse-deterrent formulations (ADFs) of prescription opioids (RxO) is an important step toward reducing misuse and abuse. Morphine-ARER (MorphaBond™ ER) is an extended-release (ER) morphine sulfate tablet formulated to deter misuse/abuse via intravenous (IV) and intranasal...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossiter, Louis F, Kwong, Winghan Jacqueline, Marrett, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974417/
https://www.ncbi.nlm.nih.gov/pubmed/32021338
http://dx.doi.org/10.2147/CEOR.S226607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6974417/
https://www.ncbi.nlm.nih.gov/pubmed/32021338
http://dx.doi.org/10.2147/CEOR.S226607

Ejemplares similares